Traders Buy Large Volume of Vor Biopharma Call Options (NYSE:VOR)

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock investors acquired 13,899 call options on the company. This represents an increase of 11,779% compared to the average daily volume of 117 call options.

Analysts Set New Price Targets

VOR has been the subject of a number of recent research reports. HC Wainwright reiterated a "neutral" rating on shares of Vor Biopharma in a research report on Friday, May 9th. Jones Trading lowered Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Stifel Nicolaus cut their price objective on Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a report on Friday, March 21st. JMP Securities reaffirmed a "market perform" rating and set a $6.00 price objective on shares of Vor Biopharma in a research note on Friday, May 9th. Finally, Oppenheimer reissued an "outperform" rating and issued a $8.00 target price on shares of Vor Biopharma in a research report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Vor Biopharma has a consensus rating of "Moderate Buy" and a consensus price target of $7.06.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds have recently modified their holdings of VOR. RA Capital Management L.P. raised its stake in shares of Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP acquired a new position in Vor Biopharma in the fourth quarter worth approximately $707,000. Jane Street Group LLC bought a new position in Vor Biopharma during the first quarter valued at approximately $140,000. Two Sigma Investments LP grew its position in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after acquiring an additional 25,930 shares in the last quarter. Finally, Northern Trust Corp grew its position in Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after acquiring an additional 44,252 shares in the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Stock Performance

Shares of VOR stock traded up $0.34 during trading on Thursday, hitting $0.89. 281,779,778 shares of the company were exchanged, compared to its average volume of 3,438,529. The firm has a market capitalization of $111.21 million, a price-to-earnings ratio of -0.54 and a beta of -0.51. The business's 50-day simple moving average is $0.35 and its 200 day simple moving average is $0.83. Vor Biopharma has a twelve month low of $0.13 and a twelve month high of $1.80.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.